Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy
- PMID: 16039240
- DOI: 10.1016/j.athoracsur.2004.02.036
Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy
Abstract
Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical